Schedule 13D ownership disclosure

Aptose Biosciences, Inc.

Common Shares · CUSIP: 03835T200

Event date: 2025-03-18

Filing-level shares
508,710
Percent of class
19.9%
  • Hanmi Pharmaceutical Co., Ltd.Reported CIK 0001904921

    Shares: 508,710 · Class: 19.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000899140-25-000439
Form type
SCHEDULE 13D/A
Filer
Aptose Biosciences Inc.
CIK
CIK 882361
Filed
Mar 20, 2025
Reporting period
Mar 18, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub